Response to letter to editor: "Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism".

Tsai CH, Salle SP, Brown JM, Newman A, Chang CC, Wu VC, Lin YH, Vaidya A

Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers.

Scribner JA, Brown JG, Son T, Jin L, McKenzie C, Nam V, Bush C, Quinonez D, Ford D, Tamura J, Gorlatov S, Summers A, Hav M, Li H, Sharma NK, Zhang X, Diedrich G, Butler S, Bonvini E, Loo D

Wnt5a-mediated Adipo-Cardiac Interorgan Communication in HFpEF.

Fatima A, Abusharkh F, Zanetta Z, Gardner S, Shi F, Kobeck E, Fortune N, Subati T, Bachmann KN, Brown JD, Gupta DK, Armstrong DWJ, Wassenaar JW, West JD, Brittain EL, Collins S, Hemnes A, Agrawal V

Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses.

Chang Y, Rath EM, Soka M, Singer ES, Trivedi G, Burns C, Austin R, Boughtwood T, Brown JS, Casauria S, Chong B, Cvetkovska J, Dunwoodie SL, Lunke S, Mattiske T, McGaughran J, Pantaleo SJ, Quinn MCJ, Semsarian C, Macciocca I, Ingles J, Fatkin D, Giannoulatou E, Bagnall RD, Australian Genomics Cardiovascular Disorders Flagship

PREVENTing Hypertensive Cardiovascular Disease: Where to Draw the Line?

McCarthy CP, McEvoy JW, Brown JM

A Tracked High-Resolution Ultrasound Endoscope for Minimally Invasive Brain Surgery.

Benson A, Weaver R, Weeks A, Hayes T, Richmond J, Landry T, Brown J

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS

Protocol to model tumor hypoxia in vitro using real-time phosphorescence-based sensing of O(2) gradients generated by metastatic cancer cells.

Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH

Maximum tolerated medication dose and other predictors of mortality in heart failure with reduced ejection fraction: retrospective cohort study.

Li JJ, Parajuli DR, Brown J, Eng-Frost J, Scherer D, Shakib S

Electronic patient-reported adverse event monitoring in academic early-phase clinical trials: A feasibility study.

Shearsmith L, Danson S, Gelcich S, Gibson A, Gordon K, Collinson F, Croft J, Griffiths E, Rogers Z, Carter R, Brown J, Velikova G, Kennedy F